z-logo
open-access-imgOpen Access
FAM87A as a Competing Endogenous RNA of miR-424-5p Suppresses Glioma Progression by Regulating PPM1H
Author(s) -
Hua Xu,
Haiping Zhang,
Tan Liu,
Yang Yang,
Haiyun Wang,
Qin Zhao,
Jun Lü
Publication year - 2021
Publication title -
computational and mathematical methods in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.462
H-Index - 48
eISSN - 1748-6718
pISSN - 1748-670X
DOI - 10.1155/2021/7952922
Subject(s) - glioma , competing endogenous rna , biology , cancer research , microrna , endogeny , cell growth , luciferase , cell , tumor progression , cell culture , microbiology and biotechnology , downregulation and upregulation , long non coding rna , gene , transfection , genetics , biochemistry
Far less has been unveiled about the functions of lncRNAs on cancers yet. Here, we reported that lncRNA FAM87A, as a ceRNA of miR-424-5p, played a vital role in glioma development. qRT-PCR result indicated that FAM87A was abnormally downregulated in glioma tissue and cells. Survival analysis suggested that the FAM87A expression was negatively correlated with the survival rate. Effects of FAM87A on human glioma cell lines were also analyzed by MTT, Edu, and transwell assays. FAM87A hastened proliferation and migration of glioma cells. MiR-424-5p, predicted target of FAM87A, was fostered in glioma, which was examined by qRT-PCR. A negative correlation was indicated between FAM87A and miR-424-5p. Results of bioinformatics, dual luciferase, and RIP assays unveiled that FAM87A and miR-424-5p act upon each other. In addition, miR-424-5p targeted 3′-UTR of PPM1H. Also, effects of miR-424-5p/FAM87A on glioma cells were identified via the cell function experiments. FAM87A suppressed PPM1H by binding to miR-424-5p competitively, thereby restraining cell proliferation, migration, and invasion. Collectively, these findings illuminated a new mechanism for glioma progression. Therefore, FAM87A may act as a feasible target for glioma treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here